Recent insider trends for Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) have caught the attention of investors. Analysts monitor insider data to understand the sentiment of a company’s largest and most important shareholders. MRNS’s insider trading patterns have some implications for where the stock might be headed.
Institutions own 23.61% of Marinus Pharmaceuticals, Inc. (MRNS)’s shares. The total value of these holdings, in millions, is $46. Among active positions in the latest quarter, 8 holders increased their positions by a total of 836681 shares, 17 holders decreased the positions by a total of 667287 shares, and 7 holders held their positions. This works out to a net increase in ownership of 169394 shares, and suggests that institutions are feeling bullish about the stock.
Among new and sold out positions, 5 holders initiated new positions by a total of 398232 shares and 8 holders exited their positions by a total of 133748 shares. This nets out to an increase of 264484 shares and is a bullish sign for MRNS.
In the last three months, insiders executed a total of 2 trades. 1 of these were buys and 1 were sells. Insider ownership increased by a total of 0 shares, which suggests that MRNS’s key executives are feeling more optimistic about the outlook for the stock. The data from the past twelve months tells a different story: insiders executed 2 buys and 2 sells, and ownership decreased by a net of 746183 shares.
Short interest is another tool that analysts use to gauge investor sentiment. It represents the number of a stock’s shares that are being shorted by investors. Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS)’s short interest is 2.08 million shares, or 13.31% of the float. This represents an increase of 8% in the number of shares being shorted compared to the previous reading, and implies that investors felt more pessimistic about the stock during the past two weeks.
Insider data can help an investor form an outlook on a stock, but it’s important to supplement this data with other information such as technical indicators to form a more complete view. A composite of 13 technical indicators that includes measures such as moving averages and momentum oscillators suggests that MRNS is a buy, which implies that MRNS is expected to outperform the market based on prior trading patterns.
Institutional ownership trends suggest that the stock is cheap and the insider trading data indicates that insiders are bullish. Technical indicators (also) suggest that Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) is undervalued.